S. Kasbari

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

H. Wakelee, D. Gandara, S. Ramalingam, 2017, The Lancet. Oncology.

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

L. Einhorn, D. Spigel, N. Leighl, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer.

W. Farrar, Randall Harris, S. Kasbari, 1999, Oncology reports.

Longitudinal study of Inflammatory, Behavioral, Clinical and Psychosocial Risk Factors for Chemotherapy-Induced Peripheral Neuropathy

T. Jusko, I. Kleckner, K. Loh, 2021, Breast Cancer Research and Treatment.

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Carlos L. Arteaga, R. Gray, K. Flaherty, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

T. Ryan, R. Goldberg, A. Ivanova, 2018, Cancer.

A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy

T. Ryan, R. Goldberg, A. Ivanova, 2016 .

SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).

K. Kelly, L. Byers, C. Gay, 2023, Journal of Clinical Oncology.